European Medicines Agency Revises Orphan Drugs Policy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Medicines Agency Revises Orphan Drugs Policy


The European Medicines Agency has revised its policy on fee reductions for orphan drugs.  The changes provide enhanced fee reductions for companies that are not micro, small, or medium-sized enterprises (SMEs) and will take affect on January 1, 2014. The policy will continue to focus on assistance to SMEs with the objective of providing incentives to support research and innovation on medicines intended for the diagnosis, prevention, or treatment of rare diseases, as recommended by EMA’s Committee for Orphan Medicinal Products (COMP). Current fee-reduction rates will still apply to applications received by EMA until Dec. 31, 2013.
 
EMA has listed the following fee reductions for non-SMEs in 2014:

  • 75% fee reduction for non-pediatric-related initial and follow-up protocol assistance (currently a 40% fee reduction)
  • 100% fee waiver for pediatric-related initial and follow-up protocol assistance (no change from 2013)
  • 10% fee reduction for initial marketing-authorization applications (currently no fee reduction)
  • 100% fee reduction for pre-authorization inspections (currently no fee reduction).

The following services will remain free-of-charge for SMEs in 2014:

  • All initial and follow-up protocol assistance
  • Initial marketing-authorization applications
  • Pre-authorization inspections
  • Post-authorization applications and annual fees in the first year of marketing authorization.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here